Valeritas Holdings, Inc. (NASDAQ:VLRX) Expected to Post Quarterly Sales of $5.11 Million

Equities analysts predict that Valeritas Holdings, Inc. (NASDAQ:VLRX) will post sales of $5.11 million for the current quarter, according to Zacks. Four analysts have issued estimates for Valeritas Holdings’ earnings, with the highest sales estimate coming in at $5.29 million and the lowest estimate coming in at $5.00 million. Valeritas Holdings posted sales of $4.89 million during the same quarter last year, which would indicate a positive year over year growth rate of 4.5%. The business is scheduled to report its next quarterly earnings results before the market opens on Friday, August 11th.

On average, analysts expect that Valeritas Holdings will report full year sales of $5.11 million for the current financial year, with estimates ranging from $20.95 million to $22.43 million. For the next fiscal year, analysts expect that the business will report sales of $28.15 million per share, with estimates ranging from $26.03 million to $30.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Valeritas Holdings.

Valeritas Holdings (NASDAQ:VLRX) last issued its quarterly earnings results on Friday, May 12th. The company reported ($6.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.72) by $4.20. The business had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $4.64 million.

A number of research analysts recently weighed in on VLRX shares. Cowen and Company started coverage on shares of Valeritas Holdings in a research report on Monday, April 17th. They set an “outperform” rating on the stock. ValuEngine raised shares of Valeritas Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Wedbush started coverage on shares of Valeritas Holdings in a research report on Monday, July 10th. They set an “outperform” rating and a $12.00 price target on the stock. Finally, B. Riley reissued a “buy” rating and set a $10.00 price target on shares of Valeritas Holdings in a research report on Wednesday, May 17th.

In other news, insider John Edward Timberlake purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The shares were bought at an average cost of $5.14 per share, with a total value of $25,700.00. Following the completion of the transaction, the insider now directly owns 23,037 shares of the company’s stock, valued at $118,410.18. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased 11,500 shares of company stock worth $57,615 over the last three months. 1.20% of the stock is owned by insiders.

A hedge fund recently bought a new stake in Valeritas Holdings stock. HighTower Advisors LLC purchased a new position in shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 27,400 shares of the company’s stock, valued at approximately $195,000. HighTower Advisors LLC owned approximately 1.67% of Valeritas Holdings at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.65% of the company’s stock.

Shares of Valeritas Holdings (NASDAQ VLRX) opened at 5.21 on Wednesday. Valeritas Holdings has a 52 week low of $4.51 and a 52 week high of $50.00. The firm has a 50-day moving average of $5.89 and a 200 day moving average of $13.58. The firm’s market capitalization is $35.65 million.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at

About Valeritas Holdings

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas Holdings (VLRX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Valeritas Holdings (NASDAQ:VLRX)

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply